A detailed history of Capital Fund Management S.A. transactions in Bio N Tech Se stock. As of the latest transaction made, Capital Fund Management S.A. holds 14,946 shares of BNTX stock, worth $1.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,946
Previous 10,100 47.98%
Holding current value
$1.69 Million
Previous $811,000 118.87%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$78.36 - $124.66 $1.17 Million - $1.86 Million
14,946 New
14,946 $1.78 Million
Q3 2023

Nov 14, 2023

BUY
$98.5 - $125.08 $1.78 Million - $2.26 Million
18,035 New
18,035 $1.96 Million
Q4 2022

Feb 13, 2023

SELL
$118.43 - $186.05 $2.33 Million - $3.65 Million
-19,644 Reduced 58.76%
13,785 $2.07 Million
Q3 2022

Nov 14, 2022

SELL
$127.65 - $183.11 $2.43 Million - $3.49 Million
-19,068 Reduced 36.32%
33,429 $4.51 Billion
Q2 2022

Aug 12, 2022

SELL
$123.25 - $186.24 $183,889 - $277,870
-1,492 Reduced 2.76%
52,497 $7.83 Million
Q1 2022

May 12, 2022

SELL
$126.25 - $231.85 $2.72 Million - $4.99 Million
-21,542 Reduced 28.52%
53,989 $9.21 Million
Q4 2021

Feb 10, 2022

BUY
$216.64 - $362.52 $4.24 Million - $7.09 Million
19,564 Added 34.96%
75,531 $19.5 Million
Q3 2021

Nov 12, 2021

BUY
$205.93 - $447.23 $6.88 Million - $14.9 Million
33,404 Added 148.05%
55,967 $15.3 Million
Q2 2021

Aug 12, 2021

BUY
$113.32 - $241.49 $2.56 Million - $5.45 Million
22,563 New
22,563 $5.05 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.5B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Capital Fund Management S.A. Portfolio

Follow Capital Fund Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.